On Feb. 24, 2022, Novavax shared extended analysis from its pivotal Phase 3 clinical trial conducted in the United Kingdom (UK), showed that a high level of efficacy for its protein-based COVID-19 vaccine, NVX-CoV2373, was maintained over a 6-month period of surveillance.

Additionally, the analysis showed vaccine efficacy of 82.5% (95% CI: 75.0, 87.7) in protection against all COVID-19 infection ﾖ both symptomatic and asymptomatic ﾖ as measured by PCR+ or anti-N seroconversion.